Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2021 Sep 30

PMID 34590601

Citations 10

Authors

Yousef M Al-Saraireh

Fatemah O F O Alshammari

Ahmed M M Youssef

Yahya M Al-Sarayra

Renata A Al-Saraireh

Ghadeer H Al-Muhaisen

Yanal S Al-Mahdy

Ahlam M Al-Kharabsheh

Seham M Abufraijeh

Hamzeh Mohammad Alrawashdeh

Affiliations

Soon will be listed here.

Abstract

Background: cervical cancer is one of the most common malignancies in women worldwide and its management remains challenging and complex. As Cytochrome4Z1 (CYP4Z1) is overexpressed in many tumours, its expression in cervical cancer is unknown. Therefore, the present study aimed to evaluate CYP4Z1 expression in cervical cancers.

Methods: CYP4Z1 expression was immunohistochemically assessed in 100 cases of cervical cancers along with ten normal cervix tissues, and the enzyme's relationship to several clinicopathological features and survival was explored.

Results: CYP4Z1 was strongly expressed in 55% of cervical cancer patients. Normal cervix samples were negative for CYP4Z1 expression. Importantly, this expression was significantly found in patients with the late stage of the disease, lymph node metastasis, and high tumour invasion ( < 0.05). Interestingly, CYP4Z1 expression was significantly correlated with shorter survival times of cervical cancer patients. Univariate analysis showed that CYP4Z1 expression, tumour stage, lymph node metastasis, and tumour invasion were significantly correlated with patient survival ( < 0.05). The multivariate analysis revealed that only CYP4Z1 expression and tumour stage were significantly correlated with patient survival ( < 0.05).

Conclusions: CYP4Z1 expression is associated with cervical cancer patients' survival and may serve as an independent predictor of poor prognosis in cervical cancer patients.

Citing Articles

The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review.

Leahy C, Osborne N, Shirota L, Rote P, Lee Y, Song B Biochem Pharmacol. 2024; 228:116241.

PMID: 38697309 PMC: 11774579. DOI: 10.1016/j.bcp.2024.116241.

Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention.

Al-Saraireh Y, Alshammari F, Abu-Azzam O, Al-Dalain S, Al-Sarayra Y, Haddad M Biomedicines. 2023; 11(11).

PMID: 38001897 PMC: 10669316. DOI: 10.3390/biomedicines11112898.

Improved methods for the detection of heme and protoporphyrin IX adducts and quantification of heme B from cytochrome P450 containing systems.

Pelletier R, Rettie A, Kowalski J J Chromatogr B Analyt Technol Biomed Life Sci. 2023; 1231:123921.

PMID: 37956555 PMC: 10842765. DOI: 10.1016/j.jchromb.2023.123921.

Phytochemical Analysis and Profiling of Antioxidants and Anticancer Compounds from (L.) subsp. Family Fabaceae.

Youssef A, Maaty D, Al-Saraireh Y Molecules. 2023; 28(9).

PMID: 37175349 PMC: 10180520. DOI: 10.3390/molecules28093939.

Phytochemistry and Anticancer Effects of Mangrove ( Lam.) Leaves and Stems Extract against Different Cancer Cell Lines.

Youssef A, Maaty D, Al-Saraireh Y Pharmaceuticals (Basel). 2023; 16(1).

PMID: 36678500 PMC: 9865503. DOI: 10.3390/ph16010004.

References

Tradonsky A, Rubin T, Beck R, Ring B, Seitz R, Mair S . A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol. 2012; 137(6):918-30. DOI: 10.1309/AJCPF3QWIG8FWXIH. View

Du W, Machalz D, Yan Q, Sorensen E, Wolber G, Bureik M . Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1. Biochem Pharmacol. 2020; 174:113850. DOI: 10.1016/j.bcp.2020.113850. View

Yan Q, Machalz D, Zollner A, Sorensen E, Wolber G, Bureik M . Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast. Biochem Pharmacol. 2017; 146:174-187. DOI: 10.1016/j.bcp.2017.09.011. View

Kowalski J, McDonald M, Pelletier R, Hanenberg H, Wiek C, Rettie A . Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1. J Med Chem. 2020; 63(9):4824-4836. DOI: 10.1021/acs.jmedchem.0c00101. View

Al-Saraireh Y, Alshammari F, Youssef A, Al-Sarayreh S, Almuhaisen G, Alnawaiseh N . Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers. Sci Rep. 2021; 11(1):5581. PMC: 7946900. DOI: 10.1038/s41598-021-85188-4. View

Zheng L, Li X, Gu Y, Lv X, Xi T . The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1. Breast Cancer Res Treat. 2015; 150(1):105-18. DOI: 10.1007/s10549-015-3298-2. View

Henry N, Hayes D . Cancer biomarkers. Mol Oncol. 2012; 6(2):140-6. PMC: 5528374. DOI: 10.1016/j.molonc.2012.01.010. View

Yang X, Hutter M, Goh W, Bureik M . CYP4Z1 - A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer. Curr Pharm Des. 2017; 23(14):2060-2064. DOI: 10.2174/1381612823666170207150156. View

Kai Chan C, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A . Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives. J Oncol. 2019; 2019:3257939. PMC: 6811952. DOI: 10.1155/2019/3257939. View

10.

Al-Saraireh Y, Alboaisa N, Alrawashdeh H, Hamdan O, Al-Sarayreh S, Al-Shuneigat J . Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues. Ecancermedicalscience. 2020; 14:1114. PMC: 7581338. DOI: 10.3332/ecancer.2020.1114. View

11.

Stark K, Dostalek M, Guengerich F . Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. FEBS J. 2008; 275(14):3706-17. PMC: 4765179. DOI: 10.1111/j.1742-4658.2008.06518.x. View

12.

Zollner A, Dragan C, Pistorius D, Muller R, Bode H, Peters F . Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biol Chem. 2008; 390(4):313-7. DOI: 10.1515/BC.2009.030. View

13.

Kalliala I, Athanasiou A, Veroniki A, Salanti G, Efthimiou O, Raftis N . Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol. 2020; 31(2):213-227. PMC: 7479506. DOI: 10.1016/j.annonc.2019.11.004. View

14.

Downie D, McFadyen M, Rooney P, Cruickshank M, Parkin D, Miller I . Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005; 11(20):7369-75. DOI: 10.1158/1078-0432.CCR-05-0466. View

15.

Yu W, Chai H, Li Y, Zhao H, Xie X, Zheng H . Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol. 2012; 264(1):73-83. PMC: 3439529. DOI: 10.1016/j.taap.2012.07.019. View

16.

Machalz D, Li H, Du W, Sharma S, Liu S, Bureik M . Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor. Eur J Med Chem. 2021; 215:113255. DOI: 10.1016/j.ejmech.2021.113255. View

17.

Murray G, Patimalla S, Stewart K, Miller I, Heys S . Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 2010; 57(2):202-11. DOI: 10.1111/j.1365-2559.2010.03606.x. View

18.

Khayeka-Wandabwa C, Ma X, Cao X, Nunna V, Pathak J, Bernhardt R . Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans. Int Immunopharmacol. 2019; 73:64-71. DOI: 10.1016/j.intimp.2019.05.003. View

19.

McDonald M, Ray S, Amorosi C, Sitko K, Kowalski J, Paco L . Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in . Drug Metab Dispos. 2017; 45(12):1364-1371. PMC: 5697098. DOI: 10.1124/dmd.117.078188. View

20.

Evangelista E, Cho C, Aliwarga T, Totah R . Expression and Function of Eicosanoid-Producing Cytochrome P450 Enzymes in Solid Tumors. Front Pharmacol. 2020; 11:828. PMC: 7295938. DOI: 10.3389/fphar.2020.00828. View